American Journal of Clinical Nutrition, Vol 60, 408-413, Copyright © 1994 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Growth retardation in children receiving long-term total parenteral nutrition: effects of ornithine alpha-ketoglutarate

AA Moukarzel, O Goulet, JS Salas, C Marti-Henneberg, AL Buchman, L Cynober, R Rappaport and C Ricour
Department of Pediatrics, Maimonides Medical Center, Brooklyn, NY.

We evaluated the effect of ornithine ketoglutarate (OKG) in reversing abnormal growth in six prepubertal children receiving total parenteral nutrition (TPN) for 5-10 y. They were 1-4 SDs below their expected 50th percentile for height. The energy and nitrogen intakes were unchanged from 8 mo before the beginning of the study until its completion. Two consecutive periods of 5 mo each were studied. OKG (15 g) was added to the parenteral solution during the first period (OKG+) but not during the second period (OKG-). Height velocity (HV) increased (P < 0.05) from a median of 3.8 cm/y to 6.45 cm/y (range 1.8-6.7) during the OKG+ period, and decreased (P < 0.05) to a median of 3.65 cm/y in the OKG- period. Plasma concentrations of insulin-like growth factor 1 (IGF1), glutamine, and glutamate increased (P < 0.05) during the OKG+ period. Variations of IGF1 concentrations correlated with HV variations (r = 0.82, P < 0.005) during both periods. This study demonstrates that OKG is associated with statural growth acceleration and increased IGF1 concentrations.

This article has been cited by other articles:

				L. Cynober Ornithine {alpha}-Ketoglutarate as a Potent Precursor of Arginine and Nitric Oxide: A New Job for an Old Friend J. Nutr., October 1, 2004; 134(10): 2858S - 2862S. [Abstract] [Full Text] [PDF]

				L. A Cynober Clinical nutrition: commercially or clinically essential? Am. J. Clinical Nutrition, July 1, 2002; 76(1): 255 - 256. [Full Text] [PDF]

				A. L Buchman Reply to LA Cynober Am. J. Clinical Nutrition, July 1, 2002; 76(1): 256 - 257. [Full Text] [PDF]